These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 7814879

  • 1. Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen.
    Hoon DS, Yuzuki D, Hayashida M, Morton DL.
    J Immunol; 1995 Jan 15; 154(2):730-7. PubMed ID: 7814879
    [Abstract] [Full Text] [Related]

  • 2. Induction of antibody response to human tumor antigens by gene therapy using a fusigenic viral liposome vaccine.
    Okamoto T, Kaneda Y, Yuzuki D, Huang SK, Chi DD, Hoon DS.
    Gene Ther; 1997 Sep 15; 4(9):969-76. PubMed ID: 9349434
    [Abstract] [Full Text] [Related]

  • 3. Differential expression of MAGE-1, -2, and -3 messenger RNA in transformed and normal human cell lines.
    Zakut R, Topalian SL, Kawakami Y, Mancini M, Eliyahu S, Rosenberg SA.
    Cancer Res; 1993 Jan 01; 53(1):5-8. PubMed ID: 8416750
    [Abstract] [Full Text] [Related]

  • 4. Characterization of a MAGE-1-derived HLA-A24 epitope-specific CTL line from a Japanese metastatic melanoma patient.
    Akiyama Y, Maruyama K, Tai S, Komiyama M, Iizuka A, Takikawa M, Ohshita C, Yamamoto A, Yamazaki N, Kiyohara Y, Yamaguchi K.
    Anticancer Res; 2009 Feb 01; 29(2):647-55. PubMed ID: 19331215
    [Abstract] [Full Text] [Related]

  • 5. A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells.
    Zhang Y, Renkvist N, Sun Z, Schuler-Thurner B, Glaichenhaus N, Schuler G, Boon T, van der Bruggen P, Colau D.
    Eur J Immunol; 2005 Apr 01; 35(4):1066-75. PubMed ID: 15756643
    [Abstract] [Full Text] [Related]

  • 6. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
    Valmori D, Liénard D, Waanders G, Rimoldi D, Cerottini JC, Romero P.
    Cancer Res; 1997 Feb 15; 57(4):735-41. PubMed ID: 9044853
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Establishment of B16-HLA-MAGE-3 melanoma cell line coexpressing HLA-A 0201/K(b) and MAGE-3 and its role in tumor vaccine evaluation].
    Song SX, Yan CZ, Zheng L, You HY, Wang JX, Liu FY.
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Jul 15; 24(7):679-82. PubMed ID: 18616910
    [Abstract] [Full Text] [Related]

  • 9. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine.
    Hu X, Chakraborty NG, Sporn JR, Kurtzman SH, Ergin MT, Mukherji B.
    Cancer Res; 1996 Jun 01; 56(11):2479-83. PubMed ID: 8653680
    [Abstract] [Full Text] [Related]

  • 10. Immunomic analysis of human sarcoma.
    Lee SY, Obata Y, Yoshida M, Stockert E, Williamson B, Jungbluth AA, Chen YT, Old LJ, Scanlan MJ.
    Proc Natl Acad Sci U S A; 2003 Mar 04; 100(5):2651-6. PubMed ID: 12601173
    [Abstract] [Full Text] [Related]

  • 11. Induction of IgG antibodies directed to a M(r) 31,000 melanoma antigen in patients immunized with vaccinia virus melanoma oncolysates.
    Berthier-Vergnes O, Portoukalian J, Lefthériotis E, Doré JF.
    Cancer Res; 1994 May 01; 54(9):2433-9. PubMed ID: 8162593
    [Abstract] [Full Text] [Related]

  • 12. Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma.
    Reynolds SR, Zeleniuch-Jacquotte A, Shapiro RL, Roses DF, Harris MN, Johnston D, Bystryn JC.
    Clin Cancer Res; 2003 Feb 01; 9(2):657-62. PubMed ID: 12576432
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity.
    Dutoit V, Rubio-Godoy V, Dietrich PY, Quiqueres AL, Schnuriger V, Rimoldi D, Liénard D, Speiser D, Guillaume P, Batard P, Cerottini JC, Romero P, Valmori D.
    Cancer Res; 2001 Aug 01; 61(15):5850-6. PubMed ID: 11479225
    [Abstract] [Full Text] [Related]

  • 16. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide.
    Nishiyama T, Tachibana M, Horiguchi Y, Nakamura K, Ikeda Y, Takesako K, Murai M.
    Clin Cancer Res; 2001 Jan 01; 7(1):23-31. PubMed ID: 11205913
    [Abstract] [Full Text] [Related]

  • 17. Expression of adaptor protein Ruk/CIN85 isoforms in cell lines of various tissue origins and human melanoma.
    Mayevska O, Shuvayeva H, Igumentseva N, Havrylov S, Basaraba O, Bobak Y, Barska M, Volod'ko N, Baranska J, Buchman V, Drobot L.
    Exp Oncol; 2006 Dec 01; 28(4):275-81. PubMed ID: 17285110
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Frequent immune responses to a cancer/testis antigen, CAGE, in patients with microsatellite instability-positive endometrial cancer.
    Iwata T, Fujita T, Hirao N, Matsuzaki Y, Okada T, Mochimaru H, Susumu N, Matsumoto E, Sugano K, Yamashita N, Nozawa S, Kawakami Y.
    Clin Cancer Res; 2005 May 15; 11(10):3949-57. PubMed ID: 15897597
    [Abstract] [Full Text] [Related]

  • 20. Tissue microarray evaluation of Melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma.
    Bolli M, Kocher T, Adamina M, Guller U, Dalquen P, Haas P, Mirlacher M, Gambazzi F, Harder F, Heberer M, Sauter G, Spagnoli GC.
    Ann Surg; 2002 Dec 15; 236(6):785-93; discussion 793. PubMed ID: 12454517
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.